Skip to content
Aminoscope
Head-to-head

Curcumin vs Low-dose naltrexone

Both get reached for in chronic pain and inflammation: an over-the-counter botanical that barely absorbs, and a compounded prescription whose best trial came back null.

By Julian RothResearch & dataUpdated October 2026

Short answer

With human clinical data on both sides, curcumin and low-dose naltrexone differ mainly in what they are for. Curcumin is marketed for anti-inflammatory use and joint pain; low-dose naltrexone is the choice for readers interested in fibromyalgia, chronic pain, autoimmune disease and ME/CFS.

Curcumin

Turmeric extract

Clinical data

Decent RCT/meta-analysis support for osteoarthritis pain — but curcumin is barely absorbed (hence piperine/formulations) and a textbook PAINS compound that lights up assays deceptively.

Full Curcumin evidence review

Low-dose naltrexone

LDN, naltrexone 1.5–4.5 mg

Clinical data

Cheap, low-risk and mechanistically interesting via TLR4 — but the largest, best-designed fibromyalgia trial was null and Cochrane calls the Crohn's evidence insufficient.

Full Low-dose naltrexone evidence review

Curcumin vs Low-dose naltrexone: head to head

FDA status / approved use

Curcumin

Sold as a supplement

Low-dose naltrexone

Naltrexone approved at 50 mg for opioid and alcohol use disorder; low-dose use is off-label
Marketed for

Curcumin

Anti-inflammatory, joint pain

Low-dose naltrexone

Fibromyalgia, chronic pain, autoimmune disease, ME/CFS, long COVID
Outcome areas

Curcumin

Joint / bone health; Immune function / inflammation

Low-dose naltrexone

Immune function / inflammation; Joint / bone health
Evidence grade

Curcumin

Clinical data

Low-dose naltrexone

Clinical data
How it works

Curcumin

Turmeric polyphenol; many lab-reported mechanisms are likely assay artifacts

Low-dose naltrexone

Blocks TLR4 on microglia and macrophages, an anti-inflammatory action beyond opioid receptors
Route and dosing

Curcumin

Oral, often in formulations engineered for better absorption

Low-dose naltrexone

Oral compounded capsule or liquid, once daily, usually at bedtime
Headline human result

Curcumin

Pain 2.04 points lower on a visual analog scale vs placebo in a meta-analysis of eight osteoarthritis RCTs

Low-dose naltrexone

No meaningful pain benefit: 0.34-point difference on an 11-point scale (p = 0.27) in a 2024 fibromyalgia trial of 99 women
Strongest evidence

Curcumin

Joint-pain meta-analysis, J Med Food 2016Curcumin evidence reviewPubMed 27533649

Low-dose naltrexone

FINAL trial, Lancet Rheumatol 2024Low-dose naltrexone evidence reviewPubMed 38258677
Key safety signal

Curcumin

Usually mild GI effects; added piperine inhibits drug-metabolizing enzymes, raising interaction risk

Low-dose naltrexone

Blocks opioid painkillers at any dose; vivid dreams and insomnia early on
How it is obtained

Curcumin

Over the counter as a dietary supplement

Low-dose naltrexone

Prescribed off-label and dispensed by compounding pharmacies

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

Curcumin has the better outcome data, and it is narrow. A meta-analysis of randomized trials found turmeric and curcumin extracts reduced arthritis symptoms, particularly knee osteoarthritis pain, comparably to NSAIDs, though the trials were short and small — and two caveats sit on top of it: plain curcumin is barely absorbed, which is why products bolt on piperine or phospholipid delivery, and medicinal chemists formally classify it as a PAINS compound that produces false positives across a huge range of assays. Low-dose naltrexone has the more interesting mechanism, TLR4 antagonism on microglia, supported by the fact that the opioid-inactive (+)-isomer does the same thing, but the trial record does not follow the mechanism: two small Stanford crossover studies in fibromyalgia were encouraging, and the larger, independently funded FINAL trial in 99 women found a between-group pain difference of 0.34 points on an 11-point scale (p = 0.27), well below any clinically meaningful threshold, while Cochrane calls the Crohn's evidence insufficient. One practical difference outweighs much of the above: naltrexone blocks opioid analgesia at any dose, so anyone taking it has to tell every clinician, dentist and surgeon, and plan around elective surgery.

Curcumin fits if

Curcumin is a reasonable low-risk try for joint pain specifically, using a formulation built for absorption and watching for the piperine-driven drug interactions, rather than expecting the cure-all its mechanistic literature implies.

Low-dose naltrexone fits if

Low-dose naltrexone is a clinician conversation rather than a purchase — no approved product exists at 1.5 to 4.5 mg, so every prescription is compounded — and it is worth having only with the null FINAL result and the opioid-blockade constraint already understood.

Curcumin vs Low-dose naltrexone: common questions

Which has stronger human evidence, curcumin or low-dose naltrexone?
Neither clearly. Both have human clinical data. The key source for curcumin is Joint-pain meta-analysis, J Med Food 2016; for low-dose naltrexone, it is FINAL trial, Lancet Rheumatol 2024.
What are the main safety concerns with curcumin and low-dose naltrexone?
For curcumin, watch for usually mild GI effects; added piperine inhibits drug-metabolizing enzymes, raising interaction risk. Low-dose naltrexone blocks opioid painkillers at any dose; vivid dreams and insomnia early on.

Key studies behind each

Curcumin

  1. Daily JW, Yang M, Park S. (2016). Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Med Food. PubMed 27533649
  2. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. (2007). Bioavailability of curcumin: problems and promises. Mol Pharm. PubMed 17999464
  3. Shoba G, Joy D, Joseph T, et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. PubMed 9619120
  4. Nelson KM, Dahlin JL, Bisson J, et al. (2017). The Essential Medicinal Chemistry of Curcumin. J Med Chem. PubMed 28074653

Low-dose naltrexone

  1. Younger J, Parkitny L, McLain D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. PubMed 24526250
  2. Hutchinson MR, Zhang Y, Brown K, et al. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. PubMed 18662331
  3. Wang X, Zhang Y, Peng Y, Hutchinson MR, Rice KC, Yin H, Watkins LR. (2016). Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Br J Pharmacol. PubMed 26603732
  4. Ludwig MD, Zagon IS, McLaughlin PJ. (2017). Featured Article: Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone. Exp Biol Med (Maywood). PubMed 28766982

The full evidence reviews

  • Curcumin: decent for joint pain, deceptive in a test tube

    Turmeric's polyphenol has respectable randomized data for arthritis pain and modest mood/metabolic signals — but it is barely absorbed, and chemists formally flag it as a compound that fools lab assays.

    Updated August 2026

  • Low-dose naltrexone: what the evidence actually shows

    LDN is a 50 mg drug taken at 4.5 mg for pain, autoimmune disease and fatigue. The TLR4 mechanism is real and interesting — but the small fibromyalgia pilots and the large one disagree, and that contrast is the whole story.

    Updated August 2026

Related comparisons